

ANEXA Nr. 5.6

Întocmirea fișei de verificare
a îndeplinirii standardelor Universității de prezentare la concurs pentru posturile de
cercetător științific gradul II
Candidat: Kubelac Milan Paul
10.01.2024

I Pentru funcțiile de **conferențiar universitar și CS II** sunt necesare cumulativ:

- a) îndeplinirea standardelor minimale naționale specifice acestor funcții, stabilite prin *Ordinul Ministrului Educației și Naționale și Cercetării Științifice privind aprobarea standardelor minimale necesare și obligatorii pentru conferirea titlurilor didactice din învățământul superior, a gradelor profesionale de cercetare-dezvoltare, a calității de conducător de doctorat și a atestatului de abilitare nr. 6129/2016;*

Anexa nr. 20 – COMISIA DE MEDICINA

Titlul	Nr. Articole ISI Autor Principal STANDARD MINIMAL	Nr. Articole ISI Autor Principal REALIZAT DE CANDIDAT	Nr. Articole ISI Coautor STANDARD MINIMAL	Nr. Articole ISI Coautor REALIZAT DE CANDIDAT	Index Hirsch STANDARD MINIMAL	Index Hirsch REALIZAT DE CANDIDAT	(ISI)Factor cumulat de Impact autor principal (FCIAP) STANDARD MINIMAL	(ISI)Factor cumulat de Impact autor principal (FCIAP) REALIZAT DE CANDIDAT
Conferențiar universitar / CSII	6	7	3	21	4	10	6	27.985

Conferențiar universitar / CSII	STANDARD MINIMAL	REALIZAT DE CANDIDAT
Nr. Articole ISI Autor Principal	6	7 1. Preda A, Ciuleanu T, Kubelac P, Todor N, Balacescu O, Achimas-Cadariu P, Iancu D, Mocan C, Bandi-Vasilica M, Lupse M, Briciu VT, Man MA, Vlad C. Outcomes of patients with cancer infected with SARS-CoV-2: results from the Ion Chircuta Oncology Institute series. Esmo Open. 2022;7(2). FI= 7.3 2. Achimas-Cadariu P, Kubelac P, Irimie A, Berindan-Neagoe I, Ruhli F. Evolutionary perspectives, heterogeneity and ovarian cancer: a complicated tale from past to present. J Ovarian Res. 2022;15(1):67. FI= 4 3. Kubelac P, Braicu C, Raduly L, Chiroi P, Nutu A, Cojocneanu R, Budisan L, Berindan-Neagoe I, Achimas-Cadariu P. Comprehensive Analysis of the Expression of Key Genes Related to Hippo Signaling and Their Prognosis Impact in Ovarian

		<p>Cancer. Diagnostics. 2021;11(2). FI= 3.992</p> <p>4. Kubelac P, Genestie C, Auguste A, Mesnage S, Le Formal A, Pautier P, Gouy S, Morice P, Bentivegna E, Maulard A, Adam J, Achimas-Cadariu P, Leary A. Changes in DNA Damage Response Markers with Treatment in Advanced Ovarian Cancer. <i>Cancers</i>. 2020;12(3). FI= 6.639</p> <p>5. Kubelac P, Craciun A, Jalba O, Gheorghe S, Lazar G, Ignat F, Lisencu C, Rancea A, Vlad C, Irimie A, Achimas-Cadariu P. Institutional results of OncoOVARIAN Dx - a novel algorithm for the preoperative evaluation of adnexal masses. <i>Journal of Buon</i>. 2020;25(3):1658-63. FI= 2.533</p> <p>6. Kubelac P, Vlad C, Berindan-Neagoe I, Irimie A, Achimas-Cadariu P. The clinical features associated with mutated BRCA1 and 2 genes in ovarian cancer patients. <i>Journal of Buon</i>. 2019;24(4):1538-43. FI= 1.695</p> <p>7. Kubelac MP, Fetica B, Vlad IC, Fulop A, Popa A, Achimas-Cadariu P. The Role of Inhibitor of DNA-binding 1 (ID-1) Protein and Angiogenesis in Serous Ovarian Cancer. <i>Anticancer Res</i>. 2014;34(1A):413-6. FI= 1.826</p>
Nr. Articole ISI Coautor	3	<p>21</p> <p>1. Roman A, Brozba A, Necula A, Muntean DD, Kubelac P, Fekete Z, et al. Usefulness of Saline Sealing in Preventing Pneumothorax after CT-Guided Biopsies of the Lung. <i>Diagnostics (Basel)</i>. 2023;13(23).</p> <p>2. Cheeseman S, Levick B, Sopwith W, Fenton H, Nam EJ, Kim D, Lim S, Martin E, Frenel JS, Bocquet F, Kubelac P, Achimas-Cadariu P, Vlad C, Chevrier M, Rouzier R, Carton M, Savva-Bordalo J, Magalhães M, Borges M, Wolf A, Becker S, Niklas N, Guergova-Kuras M, Hall G. Ovarian Real-World International Consortium (ORWIC): A multicentre, real-world analysis of epithelial ovarian cancer treatment and outcomes. <i>Front Oncol</i>. 2023 Jan 27;13:1114435.</p> <p>3. Yordanov A, Vasileva-Slaveva M, Galai N, Faraggi D, Kubelac MP, Tripac-Iacovleva I, Calleja N, Di Fiore R, Calleja-Agius J. Cancer of the Cervix in Bulgaria: Epidemiology of a Crisis. <i>Healthcare (Basel)</i>. 2023 Jan 20;11(3):318.</p> <p>4. Paşca A, Fischer-Fodor E, Monica Jiboc N, Milan Kubelac P, Saha B, Vlad C, Andrei Achimaş-Cadariu P. Meta-analyses reveal serum or plasma Interleukin-6 as a biomarker for malignant ovarian neoplasia. <i>Cytokine</i>. 2023 Jan;161:156073.</p> <p>5. Leskovská J, Miklášová N, Kubelac PM, Achimaş-Cadariu P, Valentová J, Markuliak M, Fischer-Fodor E. Antiproliferative Ruthenium Complexes Containing Curcuminoid Ligands Tested In Vitro on Human Ovarian Tumor Cell Line A2780, towards Their Capability to Modulate the NF-κB Transcription Factor, FGF-2 Growth Factor, and MMP-9 Pathway. <i>Molecules</i>. 2022 Jul 18;27(14):4565.</p> <p>6. Yordanov A, Kostov S, Slavchev S, Strashilov S, Konsoulova A, Calleja-Agius J, Di Fiore R, Suleiman</p>

		<p>S, Kubelac P, Vlad C, Achimas-Cadariu P, Vasileva-Slaveva M. Adenosquamous Carcinoma of the Uterine Cervix - Impact of Histology on Clinical Management. <i>Cancer Management and Research</i>. 2021;13:4979-86.</p> <p>7. Vlad HS, Florea M, Nucu AM, Vlad IC, Cojocaru I, Vlad M, Kubelac P, Borz MB. 3D laparoscopic salvage radical prostatectomy: mini-series report and review of the literature. <i>Journal of Buon</i>. 2021;26(3):964-9.</p> <p>8. Gaia-Oltean AI, Pop LA, Cojocneanu RM, Buse M, Zimta AA, Kubelac P, Irimie A, Coza OF, Roman H, Berindan-Neagoe I. The shifting landscape of genetic alterations separating endometriosis and ovarian endometrioid carcinoma. <i>American Journal of Cancer Research</i>. 2021;11(4):1754-69.</p> <p>9. Di Fiore R, Suleiman S, Ellul B, O'Toole SA, Savona-Ventura C, Felix A, Napolioni V, Conlon NT, Kahramanoglu I, Azzopardi MJ, Dalmas M, Calleja N, Brincat MR, Muscat-Baron Y, Sabol M, Dimitrievska V, Yordanov A, Vasileva-Slaveva M, von Brockdorff K, Micallef RA, Kubelac P, Achimas-Cadariu P, Vlad C, Tzortzatou O, Poka R, Giordano A, Felice A, Reed N, Herrington CS, Faraggi D, Calleja-Agius J. GYNOCARE Update: Modern Strategies to Improve Diagnosis and Treatment of Rare Gynecologic Tumors-Current Challenges and Future Directions. <i>Cancers</i>. 2021;13(3).</p> <p>10. Bonci EA, Titu S, Petrusan AM, Hossu C, Gata VA, Ghomi MT, Kubelac PM, Bonci TI, Piciu A, Cosnarovici M, Hitu L, Kirsch-Mangu AT, Pop DC, Lisencu IC, Achimas-Cadariu P, Piciu D, Schmidt H, Fetica B. Does Surgical Margin Width Remain a Challenge for Triple-Negative Breast Cancer? A Retrospective Analysis. <i>Medicina-Lithuania</i>. 2021;57(3).</p> <p>11. Rusu CB, Bujoreanu CE, Irimie A, Achimas-Cadariu P, Vlad C, Kubelac P, Hardo VV, Maghiar TT, Maris CV, Idris Y, Petrut B. Totally intracorporeal 3D laparoscopic orthotopic neobladder reconstruction following radical cystectomy for infiltrative bladder tumors: the experience of modified Studer and modified Y-shaped ileal reconstruction techniques. <i>Journal of Buon</i>. 2020;25(1):286-94.</p> <p>12. Gata VA, Kubelac PM, Buiga R, Vlad IC, Valean D, Muntean MV, Morariu DS, Bonci EA, Irimie A, Dina C, Achimas-Cadariu PA. The value of tumor infiltrating lymphocytes as prognostic factor for lymph node status and survival amongst patients with cutaneous malignant melanoma. <i>Journal of Buon</i>. 2020;25(6):2700-7.</p> <p>13. Moisoiu V, Stefanu A, Gulei D, Boitor R, Magdo L, Raduly L, Pasca S, Kubelac P, Mehterov N, Chis V, Simon M, Muresan M, Irimie AI, Baciut M, Stiufiuc R, Pavel IE, Achimas-Cadariu P, Ionescu C, Lazar V, Sarafian V, Notingher I, Leopold N, Berindan-Neagoe I. SERS-based differential diagnosis between multiple solid malignancies: breast, colorectal, lung, ovarian and oral cancer. <i>Int J Nanomedicine</i>. 2019;14:6165-78.</p> <p>14. Vlad C, Dina C, Kubelac P, Vlad D, Pop B, Achimas-Cadariu P. Expression of toll-like receptors in ovarian cancer. <i>Journal of Buon</i>. 2018;23(6):1725-31.</p> <p>15. Achimas-Cadariu P, Iancu M, Kubelac P, Pop F, Braicu I, Vlad C, Oskay-Ozcelik G, Schouli J. Expectations and perspectives of ovarian cancer patients about cancer management in Romania. The international NOGGO-ENGOT trial: EXPRESSION III. <i>Eur J Cancer Care (Engl)</i>. 2017;26(6).</p> <p>16. Vlad C, Kubelac P, Onisim A, Fetica B, Fulop A,</p>
--	--	---

		<p>Irimie A, Achimas-Cadariu P. Expression of CDCP1 and ADAM12 in the ovarian cancer microenvironment. Journal of Buon. 2016;21(4):973-8.</p> <p>17. Onisim A, Iancu M, Vlad C, Kubelac P, Fetica B, Fulop A, Achimas-Cadariu A, Achimas-Cadariu P. Expression of Nestin and CD133 in serous ovarian carcinoma. Journal of Buon. 2016;21(5):1168-75.</p> <p>18. Vlad C, Kubelac P, Vlad D, Irimie A, Cadariu PA. Evaluation of clinical, morphopathological and therapeutic prognostic factors in rectal cancer. Experience of a tertiary oncology center. Journal of Buon. 2015;20(1):92-9.</p> <p>19. Vlad C, Kubelac P, Onisim A, Irimie A, Achimas-Cadariu P. The role of CDCP1 (CUB domain-containing protein 1) and ADAM12 (a disintegrin and metalloproteinase 12) in ovarian cancer. Journal of Buon. 2015;20(3):673-9.</p> <p>20. Vlad C, Kubelac P, Fetica B, Vlad D, Irimie A, Achimas-Cadariu P. The prognostic value of FOXP3(+) T regulatory cells in colorectal cancer. Journal of Buon. 2015;20(1):114-9.</p> <p>21. Onisim A, Achimas-Cadariu A, Vlad C, Kubelac P, Achimas-Cadariu P. Current insights into the association of Nestin with tumor angiogenesis. Journal of Buon. 2015;20(3):699-706.</p>
Index Hirsch	4	<p>10</p> <p>https://0m10me22m-y-https-www-webofscience-com.z.e-nformation.ro/wos/woscc/citation-report/19a2f9b7-4bcb-498d-be92-ec17551a151f-c3e4d0a8</p> <p>https://www.researchgate.net/profile/Paul-Kubelac</p>
(ISI)Factor cumulat de Impact autor principal (FCiAP)	6	<p>27.985</p> <p>7.3+4+3.992+6.639+2.533+1.695+1.826</p>

5Note asupra metodei de calcul:

1. Va fi luat in considerare Indexul Hirsch calculat utilizand ISI Web of Science, Core Collection, Thomson Reuters, pentru intreaga cariera a candidatului ("all years").
2. O revista cotate ISI este o revista pentru care Thomson Reuters calculeaza si publica factorul de impact in „Journal Citation Reports”.
3. Autorul sau autorii principali ai unei publicatii se considera a fi oricare dintre urmatoarii:
 - a. Primul autor
 - b. Autorul corespondent
 - c. Alti autori, a caror contributie este indicata explicit in cadrul publicatiei a fi egala cu contributia primului autor sau a autorului corespondent
 - d. Ultimul autor
4. Factorul cumulat de impact va fi calculat pentru articolele la care candidatul este autor principal (FCiAP). FCiAP =suma factorilor de impact ai articolelor publicate de autor in calitate de autor principal in reviste cotate ISI.
5. In analiza vor fi incluse articole originale si reviews. In cazul publicatiilor in reviste cu factor de impact mai mare decat 3, pot fi luate in considerare si alte tipuri de publicatii in extenso (nu rezumate)
 - b) îndeplinirea, acolo unde este cazul, a standardelor minimale ale Universității, stabilite prin aprobarea de către Senatul UBB, la propunerea facultăților. – Nu este cazul

*Se vor lua în considerare numai publicațiile apărute, adică cele care au volum, număr, pagini și/ sau un identificator digital (DOI), conform standardelor internaționale.